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PENILAIAN KESAN SINERGI AKTIVITI ANTIBAKTERIA DIANTARA 
FRAKSI ETIL ASETAT DAUN Polyalthia longifolia (Sonn.) (PLEAF) 




Polyalthia longifolia yang berasal dari India kaya dengan pelbagai fitokimia 
berguna yang berharga untuk kesihatan manusia. Tujuan kajian ini dijalankan adalah 
untuk menilai sama ada kombinasi fraksi etil asetat Polyalthia longifolia (PLEAF) 
dengan ampisilin mempunyai aktiviti antimikrob yang sinergistik untuk menentang 
isolat MRSA dan juga untuk menilai kapasiti antioksidannya dengan tahap 
sitotoksisitinya. Penilaian aktiviti sinergi diantara fraksi PLEAF dan ampisilin 
terhadap isolat MRSA tempatan telah dijalankan dengan pelbagai kaedah 
antimikrobial iaitu kaedah peresapan cakera, kepekatan perencatan minimum (MIC), 
kepekatan bakterisidal minimum (MBC), kepekatan perencatan fraksi (FIC), asai 
waktu-membunuh dan kajian pengimbasan mikroskop elektron (SEM). Kajian kesan 
gabungan fraksi PLEAF dan ampisilin mempamerkan aktiviti antibakteria yang ketara 
terhadap MRSA. Ini terbukti apabila nilai MIC fraksi PLEAF (62.5 μg/mL) dan 
ampisilin (5000 μg /mL) didapati menurun kepada 15.63 μg/mL untuk fraksi PLEAF 
dan 2500 μg/mL untuk ampisilin masing-masing dalam kajian FIC terhadap bakteria 
MRSA. Kajian hapus-sisa radikal bebas 2,2-difenil-1-pikrilhidrazil (DPPH) dan  nitrik 
oksida (NO) menunjukkan bahawa PLEAF memiliki aktiviti antioksidan yang tinggi 
dan kombinasi fraksi PLEAF dan ampisilin mempamerkan aktiviti antioksidan 
sederhana. Penggunaan fraksi PLEAF dengan aktiviti antioksidan yang tinggi adalah 
penting untuk mencegah kesan buruk daripada penghasilan berlebihan radikal bebas 
semasa jangkitan mikrob. Kandungan jumlah fenolik (TPC) fraksi PLEAF adalah 
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sebanyak 16.822 ± 0.004 μg GAE/g  fraksi PLEAF. Sebatian fenolik mungkin 
bertanggungjawab untuk aktiviti antioksidan dan antimikrob yang dipamerkan oleh 
fraksi PLEAF. Selain itu, ujian sitotoksik 3-(4,5-dimetiltiazol-2-il)-2,5-
difeniltetrazolium bromida (MTT) fraksi PLEAF terhadap sel Vero telah 
membuktikan sebagai bukan toksik (98.14% sel viabel) dan rawatan kombinasi fraksi 
PLEAF dan ampisilin terhadap sel Vero menunjukkan peningkatan dalam sel hidup 
(52.44%) berbanding dengan sel yang dirawat dengan ampisilin sahaja. 
Kesimpulannya, fraksi PLEAF yang berkombinasi dengan ampisilin berfungsi dengan 
baik untuk membunuh bakteria MRSA rintang tempatan. Fraksi PLEAF juga 
menunjukkan aktiviti antioksidan yang menggalakkan dan meningkatkan jumlah sel 
hidup Vero semasa berkombinasi dengan ampisilin yang merupakan ciri yang penting 
bagi fraksi PLEAF yang akan digunakan dalam terapi kombinasi pada masa depan. 
Justeru kajian masa depan dicadangkan untuk menilai keupayaan fraksi PLEAF untuk 
menindas gen mecA dan menilai keupayaan kombinasi fraksi PLEAF dan ampisilin 














EVALUATION OF ANTIBACTERIAL SYNERGY OF Polyalthia longifolia 
(Sonn.) LEAF ETHYL ACETATE FRACTION (PLEAF) WITH AMPICILLIN 
AGAINST METHICILLIN-RESISTANT 
Staphylococcus aureus (MRSA) 
 
ABSTRACT 
Polyalthia longifolia which originates from India is rich with various useful 
phytochemicals which are valuable for human health. The aim of the study is to 
evaluate whether the combination of Polyalthia longifolia ethyl acetate fraction 
(PLEAF) and ampicillin exhibits synergistic antimicrobial activity against methicillin-
resistant Staphylococcus aureus (MRSA) bacteria followed by their antioxidant 
capacity and their cytotoxicity level. The evaluation of synergistic activity of PLEAF 
fraction and ampicillin against MRSA local isolate was conducted with various 
antimicrobial assays namely disc diffusion method, minimum inhibitory concentration 
(MIC), minimum bactericidal concentration (MBC), fractional inhibitory 
concentration (FIC), time-kill study and scanning electron microscopy (SEM). The 
combinational effect of PLEAF fraction and ampicillin exhibited significant 
antibacterial activity against MRSA. This is proven when the MIC values of PLEAF 
fraction (62.5 µg/mL) and ampicillin (5000 µg/mL) were found to decrease to 15.63 
µg/mL for PLEAF and 2500 µg/mL for ampicillin respectively in the FIC assay against 
the MRSA bacteria. The 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide free 
radical scavenging activities showed that PLEAF fraction possessed high antioxidant 
activity and the combinational of PLEAF fraction and ampicillin exhibited moderate 
antioxidant activity. The usage of PLEAF fraction with high antioxidants activity is 
important to prevent the adverse effect of the production of an excessive amount of 
free radicals during microbial infection. The total phenolic content (TPC) of PLEAF 
xv 
 
was 16.822 ± 0.004 µg GAE/g of PLEAF fraction. Phenolic compounds are 
responsible for the antioxidant and antimicrobial activity of PLEAF fraction. In 
addition, in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
cytotoxicity test against Vero cells, the PLEAF fraction was proven to be non-toxic 
(98.14% of cell viability). Meanwhile, the combination of PLEAF fraction and 
ampicillin treatment against the Vero cells showed an improved cell viability (52.44%) 
as compared with the ampicillin-treated group. In conclusion, the PLEAF fraction 
works well in combination with ampicillin to kill the MRSA strain. PLEAF fraction 
also showed favourable antioxidant activity and improved Vero cell viability in the 
presence of ampicillin which is an important attribute of PLEAF fraction to be used in 
the future combinational therapy. Further study is recommended to evaluate the ability 
of PLEAF fraction to suppress the mecA gene and to evaluate the in vivo antimicrobial 















CHAPTER 1:   INTRODUCTION 
 
1.1 Overview 
Nowadays, the number of bacteria that are becoming resistant to a variety of 
antimicrobial drugs is inclining dramatically and causing a serious threat to human 
health across the world. These bacteria are termed as multidrug resistant (MDR) 
bacteria. However, natural plants such as Polyalthia longifolia were known to be 
contented with valuable phytochemicals which are responsible for the antimicrobial 
activities to combat resistance in microorganisms (Dixit et al., 2014). Multidrug 
resistance (MDR) is defined as the resistance of microorganisms to the given 
antimicrobial drugs (Tanwar et al., 2014). Prolonged treatment using the same 
antibiotic contributes to the development of resistance in microorganisms that were 
initially sensitive to the given antimicrobial drugs (Giedraitiene et al., 2011).  Factors 
such as poor hygiene and sanitation, poor infection control in health care settings, 
patients are not completing the entire antibiotic course which contributes to the 
antibiotic resistance in microorganisms (Andrew, 2015). The resistant microorganisms 
such as bacteria, viruses, and fungi become resistant to the antimicrobial drugs which 
cause ineffective treatment which eventually leads to lethality effect among patients. 
Examples of bacteria which show resistance are Escherichia coli against 
cephalosporin and fluoroquinolones, Klebsiella pneumonia against cephalosporin and 
carbapenems and Mycobacterium tuberculosis against rifampicin, isoniazid, and 
fluoroquinolone (Tanwar et al., 2014).  
 
According to O’Neill (2014), it was estimated that the mortality number of 
patients due to MDR infection will increase up to 10 million people by the year 2050 
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around the world. The MDR bacteria were discovered in different regions of the world 
such as Africa, some parts of America, Eastern Mediterranean Region, Europe, South-
East Asia and Western Pacific Region (Tanwar et al., 2014). The drastic development 
of pathogen resistance to antibiotics may cause an impact to the different aspects of 
the medical field such as transplantation, care of the critical illness, chemotherapy for 
cancer, premature infant care and surgery (Worthington & Melander, 2013). This 
dramatically increases the death incidence among immune compromised patients 
caused by the infection of MDR bacteria makes these resistant pathogens to be named 
as ‘super-bugs’ (De Lima et al, 2006). This raises the attention of worldwide 
researcher to discover a new antimicrobial drug to reduce the level of MDR 
microorganism’s activity.   
 
There is a necessity to invent a new antimicrobial drug as the old antibiotics 
are not effective against the resistant microorganisms to prevent MDR infections. But, 
there is a doubt that even a new antimicrobial invention is not efficient as there are 
cases where newly discovered drugs have a short life span due to the resistance 
development against the newly discovered antimicrobial to compare against MDR 
bacterial infection (Sibanda & Okoh, 2007). Due to the high resistance of bacteria 
towards antibiotics, bioengineering of existing antibiotics should be conducted to 
overcome the bacterial resistance issues.   
 
Therefore, combination therapies between drugs should be performed against 
resistant microorganisms. Various combinations can be performed such as antibiotic 
with an antibiotic, antibiotic with a non-antibiotic adjuvant molecule, and antibiotic 
with a natural product (Sasidharan et al., 2014). In combination therapy, the combined 
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second substance can enhance the efficiency of the antibiotic by blocking the 
mechanism of resistance of the pathogens to the antibiotics. Consequently, the level of 
resistance of the pathogens against the antibiotic will be decreased and the resistant 
microbe can be easily treated. Hence, by using combinational drug therapy, the 
resistant mechanism in microorganisms can be reduced as the drugs are able to alter 
different signalling pathways in the infected cells. Their therapeutic effects are 
maximised compared to that of using a single drug therapy (Greco & Vicent, 2009). 
One such effort has been made by a study which reported the synergistic effect of 
Curcuma longa with cephalosporin antibiotics against bacteria that causes diarrhoea 
(Sasidharan et al., 2014).  
 
Medicinal plants are the richest bioresource of phytochemicals where these 
compounds were discovered to possess good antibacterial activity in combination with 
antibiotics against the resistant microorganisms. One such effort has been made by a 
study which reported the synergistic effect of Curcuma longa with cephalosporin 
antibiotics against bacteria that causes diarrhoea (Sasidharan et al., 2014). However, 
the cytotoxicity of the combination should be tested against Vero cells which are 
widely used as an initial screening test for toxicity effect. The Vero cells have been 
used in the test as it aids the use of colorimetric testing to assess cell viability (Chan et 
al., 2015).   
 
1.2 Plants as Antimicrobial Medicine 
Plants with various healing properties used in ancient medicine are now attracting the 
attention of worldwide scientists to be used in the development of antimicrobial drug 
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against multidrug-resistant (MDR) bacteria. According to World Health Organization 
(WHO), it has been reported that about 80% of the world’s population is currently 
using herbal medicine for treatment of various diseases (Ahmad et al., 2013). Plants 
rich with various phytochemicals are an important resource to be used as chemical 
substances in the synthesis of drugs, pharmaceuticals, folk medicines, food 
supplements, nutraceuticals and modern medicines (Das et al., 2010). 
 
Medicinal plants contain a vast number of bioactive compounds which are 
useful to produce antimicrobial drug due to their antimicrobial properties 
(Vijayarathna et al., 2017). Due to an increase in the number of bacterial resistance to 
the antimicrobial drugs, scientist nowadays targets medicinal plant phytochemicals to 
produce an antimicrobial drug (Moussaoui & Alaoui, 2016). These compounds are the 
secondary metabolites produced by the plants such as phenols, flavonoids, tannins, 
steroids, and alkaloids which exhibit medicinal properties of the plant (Ciocan & Bara, 
2007).  
 
The secondary metabolites known as the phytochemicals possess numerous 
beneficial activities such as anti-inflammatory, antibacterial, anti-mutagenic, anti-viral 
and antioxidant properties (Bazzaz et al., 2013). Phytochemicals such as phenols and 
flavonoids are found in medicinal plants in a large amount compared to other 
compounds (Bazzaz et al., 2013), which are an important source to treat various 




Hence, bioengineering of antimicrobial drugs such as common antibiotics 
combined with phytochemicals from the plant products would impose an efficient 
result against the MDR bacteria leading to effective treatment for healthy living of 
patients infected with the resistant bacteria. 
 
1.3 Problem statement 
Resistance to commonly used antibiotics is a rising increasing problem that in a few 
years could make infections unable to be treated and bring the state of medical care 
back to the pre-antibiotic era that existed as early as the beginning of the last century. 
During the early days, it has been discovered that microorganisms became resistant to 
single antibiotics only (Alekshun & Levy, 2007). As years pass by, the resistance level 
attained by the microorganisms has increased to multidrug resistance due to the 
increase in the frequency of selective pressure of different drugs given to the same 
microorganism (Alekshun & Levy, 2007). As a result of that, the infected bacteria in 
patients can develop resistance as it encounters the same antibiotic frequently (Rai et 
al., 2012). On the other hand, antibiotic-resistant organisms are thought to result in 
higher morbidity and mortality rates compared to antibiotic-susceptible strains 
(Cosgrove et al., 2003).  
 
The resistant microorganism normally alters their mechanism and becomes 
resistant to the given antimicrobial drug which makes treatment difficult leading to 
death among the patients. It has been claimed that there are 95 000 people who were 
infected with methicillin-resistant Staphylococcus aureus (MRSA) in the United States 
and almost 19 000 people have died from infection which were caused from Human 
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Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS), 
emphysema and Parkinson’s disease (Worthington and Melander, 2013). In Malaysia, 
the MRSA infection has increased from 17% in 1986 to 44.1% in 2007 (Sit et al., 
2017). The epidemiological data of MRSA infections are not comparable globally due 
to different population density. However, the rate of its infection was (>50%) in North 
and South America, Asia and Malta, 25-50% in China, Australia and Africa and 
(<50%) in European countries (Stefani et al., 2012).    
 
Hence, an alternative way to reduce the effect of multidrug-resistance (MDR) 
in bacteria combined with the antibacterial synergy of natural products with antibiotics 
need to be evaluated. This is to determine the combinational antimicrobial activity 
which leads to the identification of potential combinational therapies. This triggers the 
researchers and scientists to find an alternative way where a combination of natural 
products together with antibiotics is found to have a great significance synergistic 
effect in the treatment of MDR bacterial infections. Due to its rapid and non-specific 
mechanism of action, these antibacterial synergies of natural products with antibiotics 
could help to treat resistance pathogens. Hence, the current study was conducted to 
investigate the synergistic activity of Polyalthia longifolia ethyl acetate fraction 








1.4   Objectives of the Study 
         The current study was conducted with the following objectives: 
i. To investigate the synergistic activity of Polyalthia longifolia ethyl acetate 
fraction (PLEAF) with clinically used antibiotic ampicillin against MRSA, 
 
ii. To determine the antioxidant activity of PLEAF fraction with clinically 
used antibiotic ampicillin, 
 
iii. To evaluate the cytotoxicity of PLEAF fraction with clinically used 

















CHAPTER 2:   LITERATURE REVIEW 
 
2.1   Natural Products and Antimicrobial Activity 
Antibiotics are from natural substances produced by fungi but also from certain 
bacteria to defend against other bacteria (Moussaoui & Alaoui, 2016). The steady rise 
in the level of resistance of microorganisms given with the commercially available 
antibiotics in the market is now a serious global health problem. Due to the high peak 
cases involving MDR in bacteria, antimicrobial natural products have gained attention 
in the treatment to these microbes (Moussaoui & Alaoui, 2016). Natural plants are 
known as the richest bio-resource of chemical entitled for synthetic drugs, 
pharmaceuticals, folk medicines, food supplements, nutraceuticals, modern medicines 
and traditional medicines (Das et al., 2010). 
 
In the olden days, medicinal plants have been used as a therapeutic source to 
treat various diseases (Hemaiswarya et al., 2009). As it is known in the past, plant-
based medicines have provided a good alternative for human health. They tend to 
exhibit a good source of a novel drug compound (Ciocan & Bara, 2007). It has been 
predicted that about 80% of the world’s population is now depending on traditional 
medicine for their primary healthcare (Jagtap et al., 2006). This is for the reason 
natural products are cheap, safe and an effective way to be used in the treatment of 
various diseases.   
 
The therapeutic potential of traditional medicines such as antimicrobial, 
anticarcinogenic and antioxidant is because they possess secondary metabolites (Jothy 
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et al., 2013a). The secondary metabolites in plants are deposited in some or sometimes 
in all parts of the plant. Examples of these are phenol compounds, tannins, steroids 
and alkaloids (Ciocan & Bara, 2007). The presence of phenolic compounds in plants 
induces plants to exhibit anti-inflammatory, antibacterial, anti-mutagenic, antioxidant 
and antiviral properties (Bazzaz et al., 2013).  
 
Nowadays, potential plants which provide beneficial biological activity are 
being used in modern medicines as a proven drug supplement for human health 
(Ciocan & Bara, 2007). Plant bioactive compounds exert similar target sites as found 
in human as they act by resembling neurotransmitters, hormones, ligands and 
endogenous metabolites. Hence, the search for plant’s bioactive compounds to combat 
the rising resistance in microbes is a continuous process as they possess beneficial 
medicinal properties which have not been discovered (Jothy et al., 2013b).  
 
2.2   Antimicrobial evolution 
In the past years, as the chemotherapeutic properties of antibiotics have been 
discovered, it was a big relief for medical practitioners in the application of antibiotics 
to treat diseases as they are effective in the treatment against microbes. Unfortunately, 
as years pass by, the effectiveness in the treatment has been reversed as the microbes 
tend to become resistant to the given antimicrobial agents (Sibanda & Okoh, 2007). 
 
The emerging crisis of resistance to the antimicrobial agent by 
microorganisms, either gram-positive nor gram-negative bacteria is now becoming a 
serious public health problem. This is as a result that there are less or no antimicrobial 
medicines available to treat patients infected with these MDR bacteria (Magiorakos et 
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al., 2012). It was identified that not only bacteria but also viruses, fungi and parasites 
possess a raised level of MDR in them which tends to increase morbidity and mortality 
among patients. As a result, they are called ‘superbugs’ (Tanwar et al., 2014).  
 
Since there is an occurrence of prolonged infection in patients due to the high 
resistance of microorganisms, the cost required for the treatment will also increase. 
This is because the commercially available drugs are no longer effective against these 
microorganisms and hence the medical practitioners go for expensive therapies to treat 
the infected patients (Tanwar et al., 2014). Examples of resistant microorganisms are 
Klebsiella pneumoniae exhibiting extended-spectrum β-lactamases (ESBL), 
vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus 
aureus (MRSA) (Alekshun & Levy, 2007). 
 
2.3   Microbial Resistance towards Antibiotics 
In the past, research conducted in the development of new antibiotics was the most 
common activity carried out by pharmaceutical companies. The drugs that were 
invented were potentially efficient in clinical treatments. Later it was discovered that 
its efficiency has been decreased over time. This is due to the emerging of a long list 
of bacterial strains finding ways to combat the different structural drug classes. As 
such they are no longer classified as an effective treatment given. The way MDR 
bacteria used to attack the antimicrobial drugs are over limiting the invention of 





2.4   Methicillin-Resistant Staphylococcus aureus (MRSA) 
In the year 1960, methicillin-resistant S. aureus (MRSA) has been discovered after the 
discovery of penicillin-resistant S. aureus. At first, MRSA was detected in hospitals 
only and thereafter it became to propagate among the community as well (Dereskenski, 
2005). MRSA is a nosocomial infection where 52.3% of the infected patients have 
been treated in the intensive care unit (ICU) and the percentage of this infection among 
patients has increased to 37% from 1994 to 1998 (Cosgrove et al., 2003). Figure 2.1 
shows clusters of MRSA bacteria in cocci shape. 
 
The aerobic and anaerobic gram-positive cocci were initially categorized into 
two families namely Micrococcaceae and Streptococcaceae according to their 
activities, aggregation and cell morphology (Patel, 2012). The genetic studies on S. 
aureus show that S. aureus is more like the Bacillus, Lactobacillus and Streptococcus 
group compared to that of Micrococcus or Stomatococcus clusters. The S. aureus 
genus is comprised of 41 species in the group which are further grouped into coagulase 
positive (CPS) or coagulase negative (CNS) (Resch et al., 2008). Pyogenic infection 
in humans is caused by CPS S. aureus. Meanwhile, CNS S. aureus acts as an 
opportunistic pathogen where it is introduced from medical devices or colonizing 
exposed wounds (Faria et al., 2009). Table 2.1 shows the scientific classification of S. 







Table 2.1: Scientific classification of S. aureus in the taxonomical hierarchy  
Domain: Prokaryotes 
Kingdom:  Eubacteria 
Phylum: Firmicutes 






Staphylococcus aureus involves in various skin and soft infections like hair, 
impetigo and follicles (Hisata et al., 2011). The effects that S. aureus causes after being 
infected were abscess formation, suppuration, pyogenic infections and fatal 
septicaemia in human beings (Kim et al., 2005). It also causes invasive infections such 
as hospital-acquired pneumonia. Meningitis is also caused by S. aureus due to the 
infection of this pathogen in the blood or as a result of infection after brain surgery 
(Patel, 2012). The production of penicillin-binding protein (PBP2a) in S. aureus is the 
reason for the tendency of S. aureus resistant to methicillin. In addition to being 
resistant to methicillin and β-lactam antibiotics, MRSA has also become resistant to 
other antimicrobial agents like macrolide (Kim et al., 2005).  
 
The ability of MRSA to alter its penicillin-binding protein (PBP) to penicillin-
binding protein 2a (PBP2a) enables it to have less affinity for penicillin and other β-
lactam antibiotics and to maintain its transpeptidase activity (Deresinski, 2005). 
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Hence, the reduced rate for acylation and incline rate for dissociation of PBP2a to β-
lactam antibiotics enhances the resistance of MRSA to β-lactam antibiotics. 
 
The staphylococcal cassette chromosome mec (SCCmec) in MRSA genome is 
where the mecA gene complex resides within. The mecA gene complex contains the 
regulator genes, mecI and mecR together with the mecA gene (Deurenberg et al., 2007). 
Among the 2.9 million base pair of S. aureus chromosome, SCCmec represents about 
1%-2% of its genome. The coding of PBP2a occurs in the mecA gene complex. As the 
β-lactam antibiotics bind to the cytoplasmic membrane of the sensor-transducer 
receptor which was encoded by the mecR1 gene, a signal will be triggered. This signal 
will then lead to the proteolytic release of the mecI repressor from the operator region 
of the mecA gene. The PBP2a will then be expressed (Deresinski, 2005).  
 
2.5   The Mechanism of Antimicrobial Drug Inhibition on Microbes 
When a microbe is attacked by an antibiotic, those bacterial strains which are 
susceptible to the attack will eventually be destroyed. Meanwhile, those that adapt to 
its structure and modify itself to become resistant to the given antibiotic will survive 
(Giedraitiene et al., 2011). There are two types of antimicrobial therapies namely 
bactericidal drugs and bacteriostatic drugs (Russell, 2002). More than 99.9% of 
microbes will be killed using the bactericidal drugs. The bacteriostatic drugs are the 
drugs which only inhibits the growth of the microbes. There are five mechanisms by 
which an antibiotic can encounter the invading microbes such as inhibition of cell wall 
synthesis, cell membrane function, protein synthesis, and nucleic acid synthesis 
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(Kapoor et al., 2017). Figure 2.2 shows the mechanism of action of an antimicrobial 
drug on microbes. 
 
2.5.1   Inhibition of cell wall synthesis 
There are two ways by which a bacterial cell wall synthesis can be inhibited by an 
antibiotic which is lytic cell death and non-lytic cell death (Kohanski et al., 2010). In 
the lytic cell death, β-lactams and glycopeptides are the classes of antibiotics that 
disrupt cell wall biosynthesis in bacteria. The cell wall of bacteria is enclosed with a 
layer of peptidoglycan (PG) which is a covalently cross-linked polymer matrix made 
up of peptide-linked β-(1,4)-N-acetyl hexosamine 54. Transglycosylase and 
transpeptidase enzymes add disaccharide pentapeptides to extend glycan strands of the 
PG molecules to maintain the layer (Heijenoort, 2001). The mechanical strength 
provided by the PG layer enables the bacteria to survive adverse environmental 
conditions. The antibiotics given combat the bacteria by blocking the cross-linking of 
PG units by constraining the peptide bond formation reaction catalysed by 
transpeptidases called penicillin-binding protein (PBP). This indirectly reduces the 
cellular mechanical strength and structural integrity as the antibiotics are capable of 
incorporate themselves into the membrane and induce depolarization. Moreover, as 
the depletion of the PG layer occurs, cell death occurs as a result of the build-up of 
internal pressure which results in cell wall expansion and finally leading to cell death.  
 
It has been proven that lytic cell death involves many cellular processes and is 
also a more complex mechanism compared to that from non-lytic cell death. Treatment 
with using a lytic cell death enhancer such as a β-lactam to Streptococcus pneumonia 
of which lack of amidase activity known as murein hydrolase or autolysin activity will 
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either grow or undergo fatal condition. The treatment effect on the antibiotic is called 
as antibiotic tolerance 64. Autolysins are membrane-associated enzymes that degrade 
bonds within the PG strands (Novak et al., 2000). Hence, it was well understood that 
autolysins contribute to cell death lysis with the inhibition of PG layer synthesis by a 
β-lactam antibiotic and this lysis process is called lysis 64.  
 
On the other hand, bacterial strains like S. pneumoniae which have quite less, 
or no autolysin activity can still be destroyed with a β-lactam antibiotic. This is known 
as the non-lytic cell death mechanism where the killing process occurs but at a slower 
rate compared to that of lytic cell death mechanism. There are two component systems 
in bacteria that regulate the non-lytic mechanism. In S. aureus, the LytSR two-
component system regulates the autolysin activity 71 causing an effect to cell lysis 
(Groicher et al., 2000). The LytSR obstruct autolysin activity causing antibiotic 
tolerance 73. Meanwhile, LrgA regulates the entry of autolysins to the peptidoglycan 
layer. With these activities, holing-like system namely cidAB in S. aureus activates 
the autolysins enabling S. aureus to be effectively killed by β-lactams (Kohanski et al., 
2007). Figure 2.3 below elucidates the mechanism of cell wall synthesis inhibition.  
 
 
2.5.2   Inhibition of cell membrane 
The peptides which contain more than 20 amino acid residues tend to form α-helices 
to span a lipid membrane of microbes. With more peptides, the transmembrane 
orientation may destabilise the membrane or they may also oligomerise into either 
barrel-stave or toroidal-pores (Park et al., 2011). So, ions, toxins and metabolites will 
eventually flow through the pores and this prevents maintenance of homeostasis 
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leading to the death of the bacteria. In the barrel-stave mechanism, the peptides attach 
themselves to the hydrophobic core region of the membrane.  Here, they oligomerise 
and arrange themselves in alignment to expose their hydrophobic surfaces facing 
towards the interior of the lipid bilayer and the hydrophilic region facing away from 
the lipid bilayer to form the interior lining of the pore (Park et al., 2011). Whereas, in 
the toroidal-pore mechanism, the peptides initiate the membrane curvature in the 
microbe until the inner and outer surfaces extend continuously as the peptides enter 
the microbes. This leads to a channel formed through the membrane with the lumen of 
the pore being lined by the hydrophilic surface of the peptide interspersed with the 
phospholipid head groups (Brogden, 2005).  
 
Whereas, peptides act through a carpet mechanism if they are comprised of less 
than 20 amino acids as they are not capable to span a membrane. These short peptides 
settle on the surface of the microbe’s membrane until a critical threshold concentration 
is reached. At this point, they will act as a detergent by lysing or solubilising the 
membrane (Fernandez et al., 2009). Figure 2.4 illustrates the different mechanisms 
involved in the inhibition of cell membrane of microbes. 
 
2.5.3   Inhibition of protein synthesis 
There are two types of drugs inhibitors namely 50S ribosome and 30S ribosome 
inhibitors which blocks the synthesis of proteins. Examples of 50S inhibitors are 
macrolide, lincosamide, streptogramin, amphenicol and oxazolidinone. Meanwhile, 
30S inhibitors are tetracycline and aminocyclitol which is comprised of spectinomycin 
and aminoglycoside family of antibiotics. The 50S ribosome inhibitors inhibit the 
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translocation of peptidyl-tRNAs and the initiation of protein translation. This 
indirectly contributes to the hindrance of peptidyltransferase reaction which causes 
elongation of the peptide chain (Kohanski, 2010). It has been identified that macrolide, 
lincosamide and streptogramin drugs restrict the flow of peptidyl-tRNAs to the 
ribosome causing blockage of peptidyltransferase elongation reaction by steric 
inhibition and finally leading to segregation of the peptidyl-tRNA.  
 
The restriction of the flow of aminoacyl-tRNAs to the ribosome92 is carried 
out by tetracyclines (Connell et al., 2003). Meanwhile, the aminocyclitol binds the 16S 
rRNA component of the 30S ribosome subunit. Besides that, spectinomycin is not a 
factor inducing protein mistranslation 93-95, but they hinder elongation factor-
catalysed translocation which causes instability in the binding of peptidyl-tRNA to the 
ribosome. On the other hand, the interaction between aminoglycosides and the 16S 
rRNA leads to a change in the structure of the complex formed between an mRNA 
codon and its cognitive pair from aminoacyl-tRNA during translation process causing 
mistranslation of protein. Figure 2.5 elucidates the mechanism of inhibition of protein 
synthesis in pathogen by antibiotic to reduce resistance level in the pathogen. 
 
2.5.4   Inhibition of DNA synthesis 
DNA synthesis, mRNA transcription and cell division acquire the supercoiling of 
chromosome through topoisomerase-catalysed strand breakage and re-joining 
reactions. Quinolones such as fluoroquinolones attack the DNA topoisomerase and 
prohibit DNA synthesis (Fournier et al., 2000). The quinolones disrupt the topology 
of the chromosome by attacking the DNA gyrase which is the topoisomerase II and IV 
respectively. The quinolones prevent the DNA strands from re-joining by trapping the 
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topoisomerase enzymes at the DNA cleavage stage. But, this DNA topoimerase varies 
with different bacterial species which makes it difficult for the quinolone to be 
susceptible to these targets. 
 
The stable interaction complex formed between quinolone and DNA 
topoisomerase enables the bacteria to be killed by the quinolone antibiotic (Drlica & 
Malik, 2003). After the exposure of quinolone, the double-stranded DNA detach which 
were initially covalently bounded by topoisomerases as quinolones attach themselves 
to these enzymes. Due to the formation of quinolone-topoisomerase-DNA complex 
formation, DNA replication machinery becomes arrested at blocked replication forks. 
This contributes to the restriction of DNA synthesis which leads to bacteriostatic and 
causes bacterial cell death (Kohanski, 2010). Figure 2.6 shows the inhibition 
mechanism of DNA synthesis in microbes by antibiotic leading to the destruction of 
the microbes. 
 
2.6   Combinational therapy 
Simultaneous action of two or more pharmacologically active agents or the 
combination of different types of therapy is called combination therapy (Greco & 
Vicent, 2009). This means that bacteria used to fight against introduced commercial 
antibiotics are inclining day by day and getting beyond the intervention of therapeutic 
treatment itself (Alekshun & Levy, 2007). Also, the raised in the number of bacteria 
being resistant to antimicrobial agents are increasing around the world. This reduces 
the drug’s effectiveness provided for the treatment leading to treatment failure 
(Sibanda & Okoh, 2007). An introduced antimicrobial agent to a bacterium which at 
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first has a significant effect with the bacteriostatic or bactericidal action on the bacteria 
does not appear to be effective to the bacteria after a period of months to years 
(Worthington & Melander, 2013). 
 
Hence, researchers intend to find an alternative way by using a newfound 
combinational therapy of using drug combinations to combat against the MDR in 
bacteria effectively (Chanda & Rakholiya, 2011). The combinational therapy can be 
performed by using a combination of a pairing of antibiotic with an antibiotic, 
antibiotic with a non-antibiotic adjuvant molecule or antibiotic with a natural 
compound against the resistance in bacteria (Sasidharan et al., 2014). These types of 
combinational therapy are believed to reduce resistance in bacteria effectively 
(Alekshun & Levy, 2007).   
 
Combinational therapy is being used for most cancer treatments, HIV 
infections and also artemisinin-based combination treatments are the most effective 
treatment for malaria. Moreover, combination therapy is also found to be effective to 
treat bacterial infections. These can be proven with the combinational therapy 
treatment performed on Mycobacterium tuberculosis infection by using a mixture of 
four types of drugs (Worthington & Melander, 2013). 
 
The combinational therapy involving antibiotic with antibiotic pairing 
combination can be divided into three categories namely inhibition of targets in 
different pathways, inhibition of different targets in the same pathway and inhibition 
of the same target in different ways (Worthington & Melander, 2013). The 
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combination of an adjuvant molecule to the antibiotic increases the activity of the 
antibiotic such as by blocking the mechanism of resistance to the antibiotic. This will 
directly contribute to a decrease in the resistance to the antibiotic given and leads to 
the death of the microbe (Worthington & Melander, 2013). Meanwhile, a combination 
of natural product with antibiotic is found to be effective to combat MDR in bacteria. 
The chemical structures of compounds of natural products provide an infinite figure 
which serves as lead molecules where their activities can be enhanced by manipulation 
through combinations with other compounds (Sasidharan et al., 2014). Moreover, 
herbal drugs are the best modern synthetic drug that can be invented which has less or 
no side effects and considered safe to be consumed. Herbal drugs such as carvacrol, 
eugenol, and cinnamaldehyde are found to be effective against bacteria like S. aureus 
and Escherichia coli. The combination of natural products with antibiotics has also 
been reported to give synergistic, additive or antagonistic effect against different 
microbes (Araoka, 2012). 
 
One of the purpose of combinational therapy is the expectation of synergistic 
effects of the combinational antimicrobial products against the microbes. Another 
purpose is delaying resistance from occurring in bacteria when exposed to antibiotics 
(Rakholiya & Chanda, 2012). The antibiotic combinations with another partner have 
been proven to show synergism effect to many bacterial species. It couldn’t be proved 
whether it is possible to be applied in the clinical settings for better treatment (Sun et 
al., 2016). Examples of such synergism combination that can be found in vitro are 
aminoglycoside and beta-lactam antibiotics against Gram-negative bacteria, 
Pseudomonas aeruginosa, Klebsiella, E. coli and other Enterobacteriaceae (Araoka, 
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2012). At the same time, it has been identified that combinational therapy performed 
in vivo is not suitable for these microbes.  
 
It has been reported that mortality rates induced by MDR bacteria have 
declined from 57.8% to 13.3% by using combinational therapy as compared to when 
using monotherapy treatment (Sun et al., 2016). Reduction in the development of 
resistance will occur with the frequent use of combinational therapy. Also, this 
treatment will help to reverse the predominance of the infection induced by MDR 
bacteria. It is necessary to consider the two points before choosing clinically useful 
antibiotic combinations for therapeutic treatment. One of the points is the correct 
amount of dosage of each antibiotic in the combination needs to be determined. This 
is important as the precise amount of dosage used will not only reduce the cost and the 
increase of resistance, but they also reduce the toxicity effect of the drugs used on 
infected patients. Another point is that it is a challenging task to test all the possible 
combinations of drugs as there are a mounting number of drug combinations to be 
tested (Sun et al., 2016). This problem can be settled with the integration of low-cost 
HIGA with the drug combination design. This is based on observing the individual 
drug concentration below achievable human plasma concentrations, a different 
mechanism of action and clinical susceptibility breakpoints (Sun et al., 2016). 
 
2.7   Plants as a new source of antibiotic 
Over the years, traditional medicines have played the role as the main source of 
primary health care which includes Thai folk medicine (Teanpaisan et al., 2017). 
Traditional medicines use plants as the major component in their treatment which is 
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the main source of inspiration to defend the body against various diseases (Jothy et al., 
2013b). Plants have become the base for the development of medicine for many 
ailments and diseases. They also serve as a phytomedicine for treatment of diseases. It 
was predicted that 14% - 28% of higher plant species are used for medicinal purposes 
and about 74% of pharmacologically active plant components were discovered by 
using plants for ethnomedicinal values (Ncube et al., 2008).  
 
The chemical substances found in the ethnomedicinal plants provide the 
medicinal value that causes physiological action on the human body. The plants 
contain a wide array of chemical compounds such as alkaloids, glycosides, saponins, 
resins, oleoresins, and sequiterpene (Ahmad et al., 2013). These compounds are called 
as secondary metabolites which act on their potential target sites by resembling signal 
transduction molecules, hormones, ligands and endogenous metabolites and they exert 
a medicinal effect on the human body (Ciocan & Bara, 2007). Hence, it is important 
to screen plants for active compounds which play a vital role to defend the body against 
the pathogens.  
 
Researchers are constantly searching for phytochemicals from plant kingdom 
for the treatment of incurable diseases. This is necessary especially when the issue of 
resistance among bacteria has developed which needs more effective antimicrobial 
agents to kill the microbes to defend the body (Ncube et al., 2008). The polyphenolic 
and phenolic compounds in plants serve as the secondary metabolites which exhibit 
antimicrobial activity (Ncube et al., 2008). Natural products have been reported to be 
beneficial as a source of antimalarial, anti-sickling, anti-helminthic, antimicrobial, 
anti-convultant, anti-hypertensive and anti-schistosomal (Aiyegoro & Okoh, 2009). 
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On the other hand, commercial antibiotics in the market have been found to be 
causing effects of consumption such as bone marrow depression, liver damage, 
hypertensives, and neurotoxic (Aiyegoro & Okoh, 2009). The possible combination of 
antibiotic therapy with natural products may produce a synergistic effect in the 
treatment against pathogens which also delays the emergence of resistance in 
microorganisms (Chung et al., 2011). Hence, efforts should be made to discover more 
bioactive compounds in plants which have a beneficiary effect to combat against MDR 
resistance in bacterial for the possible benefit that can be gained through compound 
(Savoia, 2012).  
 
2.8   Polyalthia longifolia 
Polyalthia longifolia is an evergreen tree which is commonly used as an ornamental 
plant as it combats the noise pollution (Ghosh et al., 2008). The previous report states 
that trees with heavier branches deflect or refract the sound waves as those found in P. 
longifolia (Kumar et al., 2013). It belongs to the order Magnoliales and is under the 
family of Annonaceae. P. longifolia native from Sri Lanka. is a small medium-sized 
tree with linear-lanceolate leaves of 1 to 1.5 cm broad which is planted along roadsides 
and gardens for their beautiful appearances (Jothy et al., 2012).  It is also a stress 
tolerant plant which contains important phenolic compounds such as flavonoids, 
alkaloids, terpenoids and saponins (Sampath, 2013).  
 
Indian traditional medicinal uses almost all parts of this plant for a wide range 
of treatments such as gonorrhoea, helminthiasis, hypertension, diabetes, skin disease, 
fever and uterine disorders (Jothy et al., 2013a). It has been known that the bark of this 
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plant acts as a febrifuge (Faizi et al., 2003). Figure 2.7 pictures the P. longifolia tree. 
Also, Table 2.2 shows the taxonomical hierarchy of the plant P. longifolia. 
 
Table 2.2: Classification of the plant P. longifolia according to the taxonomical  







Genus:  Polyalthia 
Species: longifolia 
 
P. longifolia has been used as a traditional medicine in the olden days. Its bark 
is used to treat helminthiasis, hypertension, diabetes, fever and skin diseases (Manjula 
et al., 2010). Various biological activities such as antioxidant, anti-inflammatory, 
antidiabetic and antibacterial activities are found in the leaves, stem barks and roots of 
this plant (Ghosh et al., 2008; Jothy et al., 2013a; Sampath, 2013). The bark of the tree 
acts as a source to provide diterpenes, alkaloids, steroid and miscellaneous lactones 
which involves a wide variety of biological activities such as antioxidant, antifungal, 
cytotoxicity and antibacterial (Adaramola et al., 2017).  
 
Antifeedant properties have also been found in the clerodane diterpenoids 
isolated from the acetone extract of leaves. Besides that, antibacterial and antifungal 
activities are found as a result of the isolation of diterpenoids from the hexane extract 
of P. longifolia (Manjula et al., 2010). The analgesic activity and the anticancer 
